The Anti-Inflammatory Agent N-Acetyl Cysteine Exacerbates Endotoxin-Induced Hypoxemia and Hypotension and Induces Polycythemia in the Ovine Fetus

Background: Lipopolysaccharide (LPS) delivered acutely to the ovine fetus induces cerebral white matter injury and brain inflammation. N-acetyl cysteine (NAC) is potentially neuroprotective as it blocks the production of inflammatory cytokines and increases glutathione levels; however, it is unknown...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neonatology (Basel, Switzerland) Switzerland), 2010-08, Vol.98 (2), p.118-127
Hauptverfasser: Probyn, Megan E., Cock, Megan L., Duncan, Jhodie R., Tolcos, Mary, Hale, Nadia, Shields, Amy, Rees, Sandra M., Harding, Richard
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Lipopolysaccharide (LPS) delivered acutely to the ovine fetus induces cerebral white matter injury and brain inflammation. N-acetyl cysteine (NAC) is potentially neuroprotective as it blocks the production of inflammatory cytokines and increases glutathione levels; however, it is unknown whether NAC affects the physiological status of the fetus already exposed to an inflammatory environment. Objectives: Our objective was to determine whether NAC influences the physiological effects of LPS exposure in the ovine fetus. Methods: Catheterized fetal sheep underwent one of four treatments (saline, n = 6; LPS, n = 6; LPS + NAC, n = 6; NAC, n = 3) on 5 consecutive days from 95 days of gestation (term ∼147 days). Fetal arterial pressure and heart rate were recorded and blood samples collected. Results: LPS administration resulted in fetal hypoxemia and hypotension; simultaneous treatment with NAC exacerbated these effects and induced polycythemia. NAC treatment alone had no effect on the fetus. Conclusion: In the presence of LPS, NAC compromises fetal physiological status, suggesting that it may not be a suitable antenatal treatment for a fetus with evidence of inflammation.
ISSN:1661-7800
1661-7819
DOI:10.1159/000280385